Cerus Corporation Form 10-Q Summary
Business Context and Reporting Period
Cerus Corporation develops and commercializes the INTERCEPT Blood System for pathogen inactivation of blood components. Platelet and plasma systems were marketed in Europe, the Commonwealth of Independent States, the Middle East, and selected other countries; the red blood cell system remained in clinical development. The filing covers the three and six months ended June 30, 2012, compared with the corresponding 2011 periods. The 2011 comparative amounts were restated to correct previously capitalized inventory costs.
Key Financial Metrics
| Metric | Three months ended June 30, 2012 | Three months ended June 30, 2011 | Six months ended June 30, 2012 | Six months ended June 30, 2011 |
|---|---|---|---|---|
| Total revenue | $9.2 million | $6.8 million | $18.0 million | $13.4 million |
| Product revenue | $9.2 million | $6.8 million | $17.9 million | $12.9 million |
| Gross profit | $3.7 million | $2.7 million | $6.9 million | $5.8 million |
| Gross margin | Approximately 40% | Approximately 40% | Approximately 38% | Approximately 41% |
| Loss from operations | $(4.8) million | $(5.6) million | $(9.4) million | $(9.9) million |
| Net loss | $(1.9) million | $(6.4) million | $(10.7) million | $(11.5) million |
| Net loss per share | $(0.04) basic; $(0.10) diluted | $(0.13) basic and diluted | $(0.20) basic and diluted | $(0.24) basic and diluted |
| Net cash used in operating activities | Not separately provided | Not separately provided | $(9.3) million | $(11.0) million |
Revenue increased 37% in the second quarter and 35% for the six-month period. Product revenue increased 37% and 38%, respectively, driven by higher disposable-kit volumes, existing-customer purchases, and new customer adoption. Government grant revenue declined to $0.1 million for the six months from $0.4 million in the prior-year period, and none was recorded in either second quarter.
Operating expenses were $8.4 million in the quarter and $16.3 million for the six months. Research and development expense declined 14% in the quarter and 7% year to date, while selling, general and administrative expense increased 8% in both periods. The second-quarter net loss benefited from a $3.7 million non-cash gain on revaluation of warrant liabilities; the six-month period included a $0.8 million non-cash warrant revaluation loss.
At June 30, 2012, cash and cash equivalents were $26.7 million, compared with $25.5 million at December 31, 2011. Short-term investments were zero, versus $0.3 million at year-end. Working capital was approximately $18.1 million, down from $18.6 million. Inventory increased to $9.4 million from $6.4 million, while accounts receivable declined to $3.7 million from $6.1 million.
Total debt was $7.4 million, consisting principally of a $5.0 million Comerica growth capital loan and $2.5 million drawn under a revolving line of credit. Current debt was $3.7 million and non-current debt was $3.7 million. The credit agreement was secured by substantially all assets other than intellectual property and 35% of the investment in Cerus Europe B.V.; the company was in compliance with its financial covenants at quarter-end.
Material Changes Versus the Prior Comparable Period
- Product revenue rose $2.5 million in the quarter and $5.0 million for the six months.
- Six-month gross margin declined to approximately 38% from 41%, primarily due to a higher proportion of plasma kits and higher manufacturing overhead absorption; quarterly gross margin remained approximately 40%.
- Operating loss improved by $0.8 million in the quarter and $0.5 million for the six months, despite higher selling, general and administrative costs.
- Net loss improved substantially in the quarter because of the favorable warrant revaluation, but the six-month improvement was more limited.
- Operating cash burn decreased to $9.3 million from $11.0 million, while financing activities provided $10.2 million versus $0.9 million used in the prior-year period.
- Cerus sold approximately 3.1 million common shares under its at-the-market agreement for approximately $9.5 million of net proceeds during the six months, leaving less than $0.1 million available under that agreement.
- Fenwal converted all 3,327 shares of Series B preferred stock into 332,700 common shares, eliminating the $9.5 million preferred-stock balance.
- The warrant liability increased to $8.7 million from $8.0 million and remains subject to significant valuation assumptions and stock-price volatility.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management expected product revenue to continue increasing as market acceptance expands, but did not provide formal numerical revenue or earnings guidance. Research and development spending was expected to rise as Cerus pursued planned red blood cell studies and potential Phase III clinical programs in Europe and additional U.S. development activities.
Cerus stated that cash from product sales, available cash, and debt access was expected to fund requirements for at least the next twelve months, although this depends on operating performance and financing availability. Management acknowledged that additional capital may be required, particularly for red blood cell development and regulatory activities. Additional equity financing could dilute shareholders, while debt or partnering transactions could impose restrictive terms or require relinquishing rights.
The August 2011 Department of Defense grant was exhausted by March 31, 2012, and future government funding was uncertain. The company remained dependent on Fenwal and other sole-source suppliers, including suppliers of disposable-kit components and illuminators. Minimum purchase commitments totaled $4.0 million, and total contractual obligations were $15.8 million at June 30, 2012.
Key risks included continued operating losses, limited market acceptance and reimbursement, regulatory uncertainty, the need for additional clinical trials and FDA approval, product liability, foreign-exchange exposure, competition, manufacturing and supply-chain disruptions, inventory expiration or obsolescence, intellectual-property disputes, and possible covenant violations. The company also identified earthquake-related business interruption risk at its Concord, California facility.
No legal proceedings or off-balance-sheet arrangements were reported. Disclosure controls and procedures were assessed as effective as of June 30, 2012.
Important Facts for Investors to Verify
- Whether product-revenue growth continues and translates into improving gross margins and lower operating cash burn.
- The timing, cost, funding source, and regulatory progress of red blood cell clinical trials and other development programs.
- Cash runway relative to recurring losses, contractual obligations, debt maturities, and required capital expenditures.
- Compliance with Comerica’s minimum cash and revenue covenants, including the risk of accelerated repayment.
- Reliance on Fenwal and other sole-source manufacturers, supplier contract renewals, minimum purchase commitments, and inventory shelf life.
- The potential dilution from outstanding warrants, stock options, and future equity financing.
- The effect of foreign exchange, European economic conditions, reimbursement decisions, and customer concentration on revenue and collections.
- The assumptions underlying the $8.7 million warrant liability and the resulting volatility in reported earnings.